In adults with sickle cell disease hospitalized for acute chest syndrome (ACS) without pulmonary artery macrothrombosis, does therapeutic-dose anticoagulation with tinzaparin shorten ACS duration compared with prophylactic-dose anticoagulation?
Not every normotensive PE patient is truly low risk. sPESI helps identify patients who may be safe for outpatient management, while Bova helps recognize patients at risk for early deterioration despite initially stable vital signs.
Background: Sickle cell disease (SCD) affects an estimated 300,000 infants born worldwide each year and has a total estimated prevalence of 100,000 in the United States alone (Piel 2017). Within this population, over 90% of healthcare encounters are due to ...
Take Home Points Early administration of antibiotics (within 60 min) in patients with fever and neutropenia is life saving. Fever in sickle cell is an emergency and always requires cultures and antibiotics even if the child appears well. Avoid sedation ...
Background: Hemorrhage remains as one of the biggest causes of death in trauma patients. Strategies such as permissive hypotension, massive transfusion protocols, avoidance of crystalloids, TXA, and definitive hemorrhage control help decrease mortality in these patients. Empiric component blood transfusion ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
